Intellia Therapeutics, Inc. (NTLA) Reports Q4 Loss, Tops Revenue Estimates
Intellia Therapeutics (NTLA) delivered earnings and revenue surprises of +15.82% and +94.22%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?